Arcus Biosciences (RCUS) Tops Q2 EPS by 6c

Arcus Biosciences (NYSE: RCUS) reported Q2 EPS of ($1.04), $0.06 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $29 million versus the consensus estimate of $31.81 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c